Premises1. WCC Q2 backlog+~60% and sales+13% coexist with OCF53.7m versus107.8m; H1OCF275.1m versus135.8m. Sources July30 issuer https://investors.wesco.com/news-releases/news-release-details/wesco-international-reports-second-quarter-2026-results .2. EES price+5%/EBITDAmargin+110bps, CSSprice+1%/margin+140bps; UBSprice+3%/margin-40bps despitebacklog+80%. https://www.sec.gov/Archives/edgar/data/929008/000092900826000021/wcc-2q2026slides.htm .3. WCC ten suppliers32%purchases, agreements often<=60daytermination; rebateincome1.4%sales conditional, receivable264m. https://www.sec.gov/Archives/edgar/data/929008/000092900826000008/wcc-20251231.htm .4. HUBB Q2organic+10%, adjustedmargin23.9% down50bps, FCF213m versus221m;~3bnNSI fundedlargelydebt. https://hubbell.gcs-web.com/news-releases/news-release-details/hubbell-reports-second-quarter-2026-results . Rawmaterialsupplierdiversity doesnot eliminatecomponentavailability risk https://www.sec.gov/Archives/edgar/data/48898/000162828026007500/hubb-20251231.htm . Conclusion: evidence supports positive demand and some realized segmentmargincapture, not universal scarcityrents or an undervaluation. Valid conditional inference; soundness limited to issuerdata, not independentcustomeracceptance. Counterexamples: backlog can rise from projectwins rather than shortages; prepayments support profitable growth but consume cash first; acquisitionmix lowers margins without weakening demand. Startstate allcash; goalstate costedpositiveedge; bindingconstraint measuredstockpayoff pluscashcapture, not narrative demand. Exact supplierleadtime/privatecontractterms and independentcustomerdata absent. Prior qualitative favorable infrastructure; would strengthen only with repeatable acceptedcash and netstockCI>0, cannot assign quantified businessprobability from these filings.
WCC_backlog_growth_pct60
WCC_Q2_OCF_m53.7
WCC_prior_Q2_OCF_m107.8
WCC_H1_OCF_m275.1
WCC_supplier_top10_pct32
WCC_rebate_sales_pct1.4
WCC_UBS_margin_change_bps-40
HUBB_adjusted_margin_pct23.9
HUBB_margin_change_bps-50
HUBB_FCF_m213
06UTC flow and recovery review: newer USDC date, no verified spot demand
Premises:1 Circle stillSep7 net7day issuance .94bn, but USDC.com newlySep9 balance74.43675568681bn at06:01 is below Sep8 74.47079165978bn and changed from same-day05:30 74.44261970278bn. Treat intraday stock snapshots as stocks, not separately timestamped net mint events. 2 ETF Sep8 shares unchanged; actual CSV quantities stillSep4, so timing of incremental spot demand unproven. 3 Liquid explorers remain897 blocks apart and stale; unchanged operator statement describes preparation, not verified authorized payouts. Conclusion no flow/recovery trade trigger. Valid reasoning from absent evidence to no authorization, not proof flows or recovery cannot occur. Strong counterargument: issuance and restart may precede publication; prospective monitoring can reveal it, reconstructed dates cannot justify anticipatory historical entries. Sources observations17414–17416 and ETF observation, https://www.circle.com/transparency ; https://www.usdc.com/ ; https://www.ishares.com/us/products/333011/ishares-bitcoin-trust-etf ; https://www.ishares.com/us/products/337614/ishares-ethereum-trust-etf ; https://blockstream.info/liquid/api/blocks ; https://liquid.network/api/blocks ; https://x.com/Blockstream . No holdings to review.
USDC Sep9 bn74.44
USDC Sep8 bn74.47
Circle net7 bn0.94
IBIT shares1387560000
ETHA shares467680000
Liquid tip gap897
allocation0
04UTC decision: issuance is not a validated buying signal; retain $235.86 cash
Start: Catalyst49.14 cash, equity850.99, no holdings or queued orders; research run, next06UTC. Goal: repeatable costed gains before dated earnings/FDA events. Binding constraint: reliable actual-news-window payoff, including other pipeline events and executable exits. Numbered premises: (1) primary goal dates are not embargoes: FDA goalsletter https://www.fda.gov/media/151712/download plus10paired selected cases show CRL38days early and approval58days early; counterexample to generalization is selection bias, so do not estimate populationhazard. (2) RARE's actual45.86%loss was another program's Sep2Aspire failure, 17days before UX111goal; Aug4filing disclosed overlappingSep/Octreadout. Counterexample: diversification may cushion some failures, but cannot guarantee a stockpricefloor. (3) Frozen T20open/T6close costed1481 holdout-1.8556%,N2,p0,averagewinundefined,averageloss1.8556%,stress-2.2474%. It avoided known named decisions but failedpayoff; no claim all early-exit strategies fail. (4) Frozen T10open/T2close1482 holdout+3.6779%,N2,p.5,W10.0230%,L2.6672%,stress+3.2640%; both crossedearlyapprovals. Counterexample is positive return meritsresearch; it is not evidence of pre-news payoff and CI[-2.6672,10.0230]% spanszero. (5) Actual15min17354 gap43.53% refutes guaranteed stop loss, while CLIengine grossstopatlevel results1490–94 cannot repairexecution. QuarterKelly empiricallate.0917363 operational0; fund/venue/risklimits49.14/212.7475/8.5099 do not repair missingedge. Validity: premises support rejecting these two trading rules and adopting primary-first-news/fullpipeline checks. Soundness: primary dates and price arithmetic verified; N10 selected, N2holdout, missing firstglobaltimestamps, no population hazard, no livebidask model remain explicitgaps. New sources stopped changing structural conclusion; no further parametersearch. Fundamental1402,consequences1403,technical1488,simulation1495,statistical1496,indicators1499 andlessons486–488 recorded. No orders or newbook proposed. Existingmonitors/jobs retained; historicalevents need no newalerts, nothing requiresowncapitalaction before06UTC. Finalrecording phase began~04:14 after~13minresearch; finish~04:18 under43planned/45hard. Sources and all numerical eventrows persisted; localartifacts /tmp/codex-run-MaH0rf. Operational conclusion: retain49.14 cash.
Start state: Catalyst cash49.14, equity850.99, no open/pending lots in supplied context and queried own ledger. Goal: costed run-up gains with exits before actual catalyst news. Binding constraint: credible actual-window payoff and gap-aware execution, not cash availability. Gate1 requires a still-pending primary documented catalyst and the complete issuer pipeline; three of ten historical dates were already resolved before entry. Gate2 requires the actual intended window: early T20/T6 lost1.8556% holdout, late T10/T2 gained3.6779% while crossing both early approvals. Gate3 requires credible independent odds: N2 and contaminated payoffs fail even though empirical late quarterKelly=.0917363. Gate4 tests tape/affordability: TLX and SRRK above20/50SMA, but SRRK57.42 exceeds fund49.14; TLX11.98 affordable yet no qualifying event edge. Gate5 risk: maxvenueposition212.7475, fund49.14, 1%equity8.5099; historical45.86%shock caps scenario notional18.5562, not a loss guarantee. Whole-share afterhours eligibility does not remove gap risk (RARE43.53% first-postbar decline). All gates must pass; zero do. Strongest counterargument: late-window positive returns merit a prospective separately defined risk-bearing study; they cannot be renamed safe pre-event returns. Prior DRI positive-but-uncertain earnings paper study remains separately frozen. Sources1481–82,1488,1495–96 and https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all ; dated source pairs in17167–88.
fund_cash49.14
equity850.99
venue_cap212.75
nominal_risk_budget8.51
gap_scenario_notional18.56
empirical_late_quarterKelly0.09
operational_fraction0
qualified_positions0
Due04UTC flow and Liquid review: no new verified buying or recovery
Premises1 ten paired advance-goal/public-announcement cases chosen from six preexisting fund/watchlist issuers;7 goals in2025,3in2026. All known completed cases found in this bounded search, not claimed exhaustive even for these issuers. Publisher-local lead days[3,-2,38,0,-1,-1,6,4,58,32], median3.5; six positive leads. Correcting MIRM to earlier FDA public release gives35days, and Australian US dates are intervals. Three robust >=35day cases: RAREUX11138, MIRMchenodiol35, NUVLzidesamtinib58. Sponsors/SEC copies count as sameorigin; FDA independently anchors approvals, but cannot verify unavailable sponsor CRL wording independently. 2 Named-news-free T20/T6 holdoutN2 mean-1.8556%, versus SPY gross samewindows-3.3660percentagepoints excess; T10/T2 mean+3.6779%, excess+5.7206pp, both trades crossed approval news. N2 OLS haszero residual degrees of freedom: correlation-1 and fittedbeta have no inferentialvalue. TrainN5 late-rule corr.6751/beta2.5682/alpha3.2273% is selected and3TLXclustered; no stablemarketalpha. 3 Ordinary empirical binary-payoff quarterKelly for late-rule p.5,W10.023035%,L2.667224% is.0917363, but it measures contaminated selected payoffs; operational0. Early-rule holdoutno wins, averagewinundefined, no positiveedge. Fundledger3losses includes2operatorliquidations; no unbiased independent p/W/L. Validity: one verified counterexample refutes guaranteed timing safety. Soundness: sampledcounts cannot quantify population risk, no posteriorprobability derived. Evidence to move allocation: preregistered prospective fullcalendar cohort, earliestnewstimestamps, allpipeline overlaps, independent actualexit-cost returns and executable risk; positivecurrentN2 alone insufficient. Sources pairedobservations17167–88/17285–90; https://www.fda.gov/media/151712/download ; prices https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all .
timing_cases10
issuers6
lead_atleast35days3
local_median_lead_days3.5
price_train_N5
price_holdout_N2
late_holdout_news_crossings2
early_excess_pp-3.37
late_excess_pp5.72
holdout_OLS_residual_df0
empirical_late_quarterKelly0.09
allocation0
Rare gap sensitivity: small assumed hazard can erase routine gains
Premises: actual closed RARE trade lost45.8600619% (query_trades fund=catalyst); a hypothetical ordinary event earns1.5% net. The 1.5% gain and independent per-event hazards0%,1%,5%,10% are assumptions, not a fitted return distribution or estimated FDA hazard. NumPy seed20260909 simulates50000 paths of10 events, fully reinvesting a hypothetical49.14. At5% assumed hazard, expected arithmetic return/event=-0.8680031%; terminal p5/median/p95=$16.2255/$57.0290/$57.0290, terminal loss frequency40.296%, p95 maximum drawdown69.8027%. Across10events expected number of shocks0.5; median profit hides severe left-tail damage. At1% hazard loss frequency9.472%; at10%64.868%. Break-even arithmetic hazard=.015/(.015+.458600619)=3.16723%; this threshold is sensitivity, not measured likelihood. Strongest counterargument: earlier exits could reduce hazard substantially and ordinary payoff may differ; selected10case sample cannot identify either sufficiently. Bootstrap or Monte Carlo cannot manufacture missing decision populations or executable quotes. Account riskbudget8.5099 divided by historical shock fraction yields notional18.5562, a scenario cap only, never a hard bound on future gaps. Operational allocation0 until actual-window costed edge and risk are calibrated. Source runway:query_trades?fund=catalyst and https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-phase-3-aspire-results-angelman-syndrome ; observations17355–58.
paths50000
events_per_path10
assumed_hazard0.05
assumed_ordinary_return_pct1.5
shock_pct-45.86
expected_return_pct-0.87
terminal_p516.23
terminal_median57.03
terminal_loss_pct40.3
drawdown_p95_pct69.8
break_even_hazard_pct3.17
allocation0
SRRK CLI momentum holdout: execution model unsuitable for FDA gaps
Diagnostic only. Ran supplied backtest CLI momentum20, stop5%, target10%, days730 on IEX; then imported its unchanged engine and strategy for SIP train through2025 and held-out2026 throughSep8, with20 prior bars for warmup and flat warmup trading. Holdout {"fund":"catalyst","split":"holdout","symbol":"SRRK","bars":191,"returnPct":-28.08145949402554,"buyAndHoldPct":31.96966214663297,"maxDrawdownPct":34.1333589954249,"winRate":16.666666666666664,"avgTradePct":-1.800182191174515,"N":18}. Inspection of /app/agent/dist/backtest/engine.js shows zero fees/slippage, same-close signal entry and stop fills at the exact stop even if price gaps below it. That stop treatment is contradicted by RARE's actual ledger and 15-minute gap audit17354. Positive gross results cannot be trusted for this mandate, and no parameter was selected for live use. Buy-and-hold includes warmup and must not be used as aligned holdout excess return. Source https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all ; raw and split observations17369–78/17387–91. The independent costed vectorbt calendar tests1481–82, with exposure audit, answer tonight's question; this CLI diagnostic supplies no position size.
return-28.08
drawdown34.13
win rate16.67
sample18
fees_modeled0
slippage_modeled0
allocation0
TLX CLI momentum holdout: execution model unsuitable for FDA gaps
Diagnostic only. Ran supplied backtest CLI momentum20, stop5%, target10%, days730 on IEX; then imported its unchanged engine and strategy for SIP train through2025 and held-out2026 throughSep8, with20 prior bars for warmup and flat warmup trading. Holdout {"fund":"catalyst","split":"holdout","symbol":"TLX","bars":191,"returnPct":14.648436875678472,"buyAndHoldPct":24.01656314699794,"maxDrawdownPct":18.637582304526767,"winRate":40,"avgTradePct":0.8371212121212129,"N":15}. Inspection of /app/agent/dist/backtest/engine.js shows zero fees/slippage, same-close signal entry and stop fills at the exact stop even if price gaps below it. That stop treatment is contradicted by RARE's actual ledger and 15-minute gap audit17354. Positive gross results cannot be trusted for this mandate, and no parameter was selected for live use. Buy-and-hold includes warmup and must not be used as aligned holdout excess return. Source https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all ; raw and split observations17369–78/17387–91. The independent costed vectorbt calendar tests1481–82, with exposure audit, answer tonight's question; this CLI diagnostic supplies no position size.
return14.65
drawdown18.64
win rate40
sample15
fees_modeled0
slippage_modeled0
allocation0
MIRM CLI momentum holdout: execution model unsuitable for FDA gaps
Diagnostic only. Ran supplied backtest CLI momentum20, stop5%, target10%, days730 on IEX; then imported its unchanged engine and strategy for SIP train through2025 and held-out2026 throughSep8, with20 prior bars for warmup and flat warmup trading. Holdout {"fund":"catalyst","split":"holdout","symbol":"MIRM","bars":191,"returnPct":22.16509767375947,"buyAndHoldPct":40.20284547119313,"maxDrawdownPct":15.199708089039069,"winRate":50,"avgTradePct":1.5664072813636993,"N":16}. Inspection of /app/agent/dist/backtest/engine.js shows zero fees/slippage, same-close signal entry and stop fills at the exact stop even if price gaps below it. That stop treatment is contradicted by RARE's actual ledger and 15-minute gap audit17354. Positive gross results cannot be trusted for this mandate, and no parameter was selected for live use. Buy-and-hold includes warmup and must not be used as aligned holdout excess return. Source https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all ; raw and split observations17369–78/17387–91. The independent costed vectorbt calendar tests1481–82, with exposure audit, answer tonight's question; this CLI diagnostic supplies no position size.
return22.17
drawdown15.2
win rate50
sample16
fees_modeled0
slippage_modeled0
allocation0
IONS CLI momentum holdout: execution model unsuitable for FDA gaps
Diagnostic only. Ran supplied backtest CLI momentum20, stop5%, target10%, days730 on IEX; then imported its unchanged engine and strategy for SIP train through2025 and held-out2026 throughSep8, with20 prior bars for warmup and flat warmup trading. Holdout {"fund":"catalyst","split":"holdout","symbol":"IONS","bars":191,"returnPct":-14.070477285394468,"buyAndHoldPct":-30.70625610948192,"maxDrawdownPct":18.321309831926,"winRate":31.25,"avgTradePct":-0.8359489928864545,"N":16}. Inspection of /app/agent/dist/backtest/engine.js shows zero fees/slippage, same-close signal entry and stop fills at the exact stop even if price gaps below it. That stop treatment is contradicted by RARE's actual ledger and 15-minute gap audit17354. Positive gross results cannot be trusted for this mandate, and no parameter was selected for live use. Buy-and-hold includes warmup and must not be used as aligned holdout excess return. Source https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all ; raw and split observations17369–78/17387–91. The independent costed vectorbt calendar tests1481–82, with exposure audit, answer tonight's question; this CLI diagnostic supplies no position size.
return-14.07
drawdown18.32
win rate31.25
sample16
fees_modeled0
slippage_modeled0
allocation0
RARE CLI momentum holdout: execution model unsuitable for FDA gaps
Diagnostic only. Ran supplied backtest CLI momentum20, stop5%, target10%, days730 on IEX; then imported its unchanged engine and strategy for SIP train through2025 and held-out2026 throughSep8, with20 prior bars for warmup and flat warmup trading. Holdout {"fund":"catalyst","split":"holdout","symbol":"RARE","bars":191,"returnPct":1.8975920520518441,"buyAndHoldPct":-59.17695473251029,"maxDrawdownPct":22.621906250000023,"winRate":33.33333333333333,"avgTradePct":0.3544089355959463,"N":15}. Inspection of /app/agent/dist/backtest/engine.js shows zero fees/slippage, same-close signal entry and stop fills at the exact stop even if price gaps below it. That stop treatment is contradicted by RARE's actual ledger and 15-minute gap audit17354. Positive gross results cannot be trusted for this mandate, and no parameter was selected for live use. Buy-and-hold includes warmup and must not be used as aligned holdout excess return. Source https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all ; raw and split observations17369–78/17387–91. The independent costed vectorbt calendar tests1481–82, with exposure audit, answer tonight's question; this CLI diagnostic supplies no position size.
return1.9
drawdown22.62
win rate33.33
sample15
fees_modeled0
slippage_modeled0
allocation0
04UTC helium deep-dive decision: documented pricing power, no qualified trade
Independent audit caught a reporting-basis difference, not a portfolio-return error: vectorbt trades Return uses entry notional as denominator, while fully invested equity includes entry fees. Correct cash-return=P n L/(size*entryprice+entryfee), equivalent to dividing earlier trade returns by1.0025. All6baselineholdout compounded cash returns now reconcile to portfolio returns within1e-8 percentagepoint. Thus averagewins/losses/expectancy and bootstrapCI in1460–1465 should use corrected observations; return,drawdown,N,winrate,quarterKelly0 unchanged. DailyBTC/ETH/SOL corrected expectedpayoffs-2.581506/-3.613642/-3.442937%; hourly-2.609239/-3.451847/-3.175189% (see exactrecordedobservations). Rejection remains. Filesresearch/test_supply.py nowcashbasis; backtests_cash_basis.json corrected96rows, audit_sim.py verification. Rawprice/source https://runway.adityaperswal.workers.dev/data/crypto-bars ; supply https://stablecoins.llama.fi/stablecoin/2 . No conversion of invalidhourlyexec into tradeapproval.
1. Independent cash-ratio verification includes both entry andexitfees/slippage and reproduces LIN-5.5797222653%/APD-2.6455982443%. Uniqueorderedbars and validpositiveOHLC checked. Daily bucket timestamps are not execution clock observations. https://runway.adityaperswal.workers.dev/data/stock-bars .2. list_jobs actual03:15 output116 confirms15panels+END andexit0; CENTCOM HTTPerror/Bombardier challenge are missing coverage. Existing jobs12/18/36/73/116 preserved. Tool lookup https://runway.adityaperswal.workers.dev .3. OriginalCMDPDF exacthref fetched200 after browser normalized plus characters returned403; JS webcast registration exposed no transcript. OriginalQ&A remains unread; no authenticated access assumed. https://ir.aspisotopes.com/news-events/capital-markets-day .4. DueFRO military primary reread confirms sameSep8five-carrier claim, not fresh cargo/IMO/insurance/fixturecash. https://www.centcom.mil/MEDIA/PUBLIC-RELEASES/Article/4593050/us-destroys-5-irgc-tankers-after-iran-targets-another-american-warship/ .5. Emptybook fromcontext and query_trades; two historicaloperatorliquidations provide no slippagebenchmark or averagedrawdown/stopcalibration. Failededge means no executablelimit,stop ortarget fabricated. Schema rejection of simulation figures arrays was corrected to scalar1477; initial attempted write was not a savedanalysis.
bars_per_distributor1174
invalid_OHLC0
duplicate_dates0
collector_panels15
active_jobs5
open_positions0
queued_orders0
proposed_usd0
APD required CLI diagnostic, not execution validation
Ran node /app/agent/dist/backtest.js --symbols LIN,APD --strategy breakout --lookback 20 --days 730 --stop-pct 3 --target-pct 6. Source https://runway.adityaperswal.workers.dev/data/stock-bars . CLI501bars with same-close/IEX and different signal exits; costs and15minute venue routing not modeled. Do not compare as independent replication of next-openSIP10session rule. Record complete summary {"symbol":"APD","bars":501,"returnPct":1.7990376141840292,"buyAndHoldPct":8.727246170418645,"maxDrawdownPct":9.92688947378435,"winRate":35.294117647058826,"avgTradePct":0.06768413949676041,"sample":34}. Qualification uses1454–1459, which reject both. No orders.
return1.8
drawdown9.93
win rate35.29
sample34
buy_hold_pct8.73
average_trade_pct0.07
LIN required CLI diagnostic, not execution validation
Ran node /app/agent/dist/backtest.js --symbols LIN,APD --strategy breakout --lookback 20 --days 730 --stop-pct 3 --target-pct 6. Source https://runway.adityaperswal.workers.dev/data/stock-bars . CLI501bars with same-close/IEX and different signal exits; costs and15minute venue routing not modeled. Do not compare as independent replication of next-openSIP10session rule. Record complete summary {"symbol":"LIN","bars":501,"returnPct":-1.16069880047881,"buyAndHoldPct":1.0794706276042287,"maxDrawdownPct":8.752398381628264,"winRate":36.11111111111111,"avgTradePct":-0.022644835699121693,"sample":36}. Qualification uses1454–1459, which reject both. No orders.